Subject:  Cancer fighting proteins (Guru)....
Date:     Fri, 17 Sep 1999 094258 -0500 (CDT)
From:     "Roy L. Beavers" 
To:       emfguru 
--------------------------------------------------


.....Note, if EMF is "disturbing" the normal performance of proteins
(like the one cited below) ... then you have a very credible explanation
for some of the epidemiological results that are being observed -- higher
cancer incidence (childhood leukemia, brain cancer, etc.) in some EMF
exposure situations.....

Roy Beavers (EMFguru)......
rbeavers@llion.org.......
.....It is better to light a single candle than to curse the darkness.....
EMF-L web-site can be found at: 
EMF-L archives can be found at: 
..................PEOPLE ARE MORE IMPORTANT THAN PROFITS..................

..........DO YOU KNOW OF OTHERS WHO SHOULD BE ON THIS LIST??????..........

     _________________________________________________________________
   
03:56 PM ET 09/16/99

Cancer-Fighting Protein Found


 By PAUL RECER=
 AP Science Writer=
           WASHINGTON (AP) _ Researchers have found that a protein that
 helps regulate blood clotting can be changed into a cancer fighter
 that starves tumors.
           The discovery adds to a growing list of proteins known to block
 cancer by preventing blood vessel formation.
           Researchers led by Judah Folkman and Michael S. O'Reilly at
 Boston's Children's Hospital and Harvard Medical School found that
 antithrombin, a protein that controls the formation of blood clots,
 changes in molecular shape to become a cancer fighter. The
 transformation occurs when it is cut. [...garbled sentence here....] 
 Human trials of those proteins are to start soon.
           The study of the new protein appears Friday in the journal
 Science.
           O'Reilly said he found the anticancer properties of the reshaped
 antithrombin molecule while studying a curious thing about small
 cell lung cancer.
           When patients with this cancer are treated with radiation, the
 primary tumor is suppressed, but very often the patient then
 develops cancer at another site, said O'Reilly. The new cancer
 developed only when the first cancer was in retreat.
           ``It seemed that the big tumor was preventing formation of
 little ones,'' he said.
           To test this, O'Reilly put lung cancer cells under the skin
 above both back hips of laboratory mice.
           ``Whichever tumor was the first to form became the dominant
 tumor,'' he said. The dominant tumors formed bulging masses, while
 on the oppositeaction about like that of angiostatin and
 endostatin, said Folkman.
           ``The key finding here is that the body apparently has a
 storehouse of proteins whose only function is to turn off blood
 vessel formation,'' said Folkman. ``This is a surprise.''
           Folkman said he expects other such proteins to be discovered.
           ``We don't know how many,'' he said. ``We keep finding them.''
           The so-called antiangiogenic proteins work by preventing tumors
 from growing blood vessels that tap the blood circulation system of
 the patient. Without this connection, the tumor cells are starved
 for oxygen and nutrients. In laboratory mouse studies, these
 proteins cause tumors to shrivel and even disappear.
           Human trials of endostatin and angiostatin are to begin this
 fall in Boston and the National Cancer Institute is planning to
 sponsor two clinical trials at other hospitals. These early studies
 are designed only to test the safety of the drugs. In monkey tests,
 the drugs have shown no toxic effects, even when given at high
 doses.
           O'Reilly said it may take several years before aaAT is ready for
 human trials.

     _________________________________________________________________
   



Archive provided courtesy of WaveGuide, http://www.wave-guide.org
Reprinted with permission of Roy Beavers, http://www.emfguru.com